“病证结合”多主要终点评价法在中医药临床研究中的应用(4)
[17]Teixeira-Pinto A，Mauri L.Statistical analysis of noncommensurate multiple outcomes[J].Circ Cardiovasc Qual Outcomes，2011，4(6)：650-656.
[18]李景.糖尿病腎病中医药疗效综合评价体系研究[D].北京：北京中医药大学，2012.
[19]陈磊，梁伟雄，吕志平.生脉胶囊治疗慢性充血性心力衰竭临床疗效的TOPSIS 法综合评价[J].南方医科大学学报，2010，30(4)：820-822.
[20]Freemantle N，Calvert M，Wood J，et al.Composite endpoints in randomized trials：greater precision but with greater uncertainty[J].JAMA，2003，289(19)：2554-2559.
[21]Rauch G，Jahn-Eimermacher A，Brannath W，et al.Opportunities and challenges of combined effect measures based on prioritized outcomes[J].Stat Med，2014，33(7)：1104-1120.
[22]Huang P，Woolson RF，O′Brien PC.A rank-based sample size method for multiple outcomes in clinical trials[J].Stat Med，2008，27(16)：3084-3104.
[23]O′Brien PC.Procedures for comparing samples with multiple endpoints[J].Biometrics，1984，40(4)：1079-1089.
[24]Baraniuk S，Seay R，Sinha AK，et al.Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes[J].Prog Cardiovasc Dis，2012，54(4)：357-361.
[25]Cook RJ，Farewell VT.Guidelines for monitoring effieaey and toxieity responses in clinieal trials[J].Biometrics，1994，50(4)：1146-1152.
[26]Sozu T，Sugimoto T，Hamasaki T.Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables[J].Biom J，2012，54(5)：716-729.
[27]杨卫娇.多终点指标下两阶段适应性设计的样本量再估计[D].上海：华东师范大学，2011.
(2017-05-10收稿 责任编辑：徐颖), 百拇医药(胡晶 刘卫红 张会娜)
[18]李景.糖尿病腎病中医药疗效综合评价体系研究[D].北京：北京中医药大学，2012.
[19]陈磊，梁伟雄，吕志平.生脉胶囊治疗慢性充血性心力衰竭临床疗效的TOPSIS 法综合评价[J].南方医科大学学报，2010，30(4)：820-822.
[20]Freemantle N，Calvert M，Wood J，et al.Composite endpoints in randomized trials：greater precision but with greater uncertainty[J].JAMA，2003，289(19)：2554-2559.
[21]Rauch G，Jahn-Eimermacher A，Brannath W，et al.Opportunities and challenges of combined effect measures based on prioritized outcomes[J].Stat Med，2014，33(7)：1104-1120.
[22]Huang P，Woolson RF，O′Brien PC.A rank-based sample size method for multiple outcomes in clinical trials[J].Stat Med，2008，27(16)：3084-3104.
[23]O′Brien PC.Procedures for comparing samples with multiple endpoints[J].Biometrics，1984，40(4)：1079-1089.
[24]Baraniuk S，Seay R，Sinha AK，et al.Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes[J].Prog Cardiovasc Dis，2012，54(4)：357-361.
[25]Cook RJ，Farewell VT.Guidelines for monitoring effieaey and toxieity responses in clinieal trials[J].Biometrics，1994，50(4)：1146-1152.
[26]Sozu T，Sugimoto T，Hamasaki T.Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables[J].Biom J，2012，54(5)：716-729.
[27]杨卫娇.多终点指标下两阶段适应性设计的样本量再估计[D].上海：华东师范大学，2011.
(2017-05-10收稿 责任编辑：徐颖), 百拇医药(胡晶 刘卫红 张会娜)